Literature DB >> 34567398

A Rare Case of Steroid-Resistant Neurosarcoidosis of the Cavernous Sinus With Optic Neuropathy: A Case Report.

Shiva Barforoshi1, Nikhil A Patel1, Alvin P Singh1, Terrence Li2, Benjamin Mba3.   

Abstract

Sarcoidosis is an inflammatory disease that presents with nervous system involvement in 5-10% of cases, commonly known as neurosarcoidosis.1 While there are no randomized controlled trials for the treatment of neurosarcoidosis, expert opinion supports initial treatment with corticosteroids and the use of steroid-sparing or anti-TNF agents in refractory or severe cases. We report a case of a 48-year-old African American male with a past medical history of biopsy-proven hepatic and renal sarcoidosis and progressive headache, dizziness, and blurry vision for 5 months, presenting with an acute exacerbation of right-sided vision loss over one day. MRI of the brain revealed a dural-based mass extending into the right cavernous sinus and compressing the right optic nerve. Given the pathological confirmation of systemic granulomatous disease consistent with sarcoidosis, clinical manifestations, bilateral hilar and mediastinal lymphadenopathy, MRI findings typical of central nervous system inflammation, and exclusion of other possible etiologies, the patient was diagnosed with probable neurosarcoidosis. Corticosteroids initially resolved his symptoms; however, he suffered an acute relapse. Combination therapy with corticosteroids plus mycophenolate mofetil (MMF) led to the eventual resolution of his symptoms. Only 8 cases of neurosarcoidosis involving the cavernous sinus have been reported. Our patient represents the only reported case of probable neurosarcoidosis of the cavernous sinus with optic neuropathy successfully treated with corticosteroid plus MMF combination therapy. We highlight the need to consider early, aggressive treatment in cases of neurosarcoidosis with optic neuropathy and to develop criteria to guide treatment strategy based on neurolocalization and the degree of neurological disability.
© The Author(s) 2021.

Entities:  

Keywords:  case report; neuroimmunology; neuroophthalmology; neurosarcoidosis; ophthalmoplegia; rheumatology

Year:  2021        PMID: 34567398      PMCID: PMC8442148          DOI: 10.1177/1941874421993644

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  8 in total

Review 1.  Corticosteroid treatment in sarcoidosis.

Authors:  J C Grutters; J M M van den Bosch
Journal:  Eur Respir J       Date:  2006-09       Impact factor: 16.671

2.  Cavernous sinus syndrome due to neurosarcoidosis in adolescence: a diagnosis not to be missed.

Authors:  F Rosini; D Bennett; A Cerase; L Volterrani; A Federico; P Rottoli; Alessandra Rufa
Journal:  Neurol Sci       Date:  2016-11-23       Impact factor: 3.307

3.  Neurosarcoidosis: leptomeninigeal, cavernous sinus and pituitary involvement.

Authors:  L Bicart-Sée; M Roriz; H Chabriat; F Buffon-Porcher; E Cognat
Journal:  QJM       Date:  2017-06-01

4.  Solitary cavernous sinus neurosarcoidosis mimicking neurosyphilis.

Authors:  Dong Ha Kim; Won Ho Cho; Kyu Sup Cho; Seong Heon Cha
Journal:  J Korean Neurosurg Soc       Date:  2014-01-31

5.  Cavernous sinus syndrome due to sarcoidosis: a case report.

Authors:  Cheng-Shu Chang; Wei-Liang Chen; Chien-Te Li; Pao-Yu Wang
Journal:  Acta Neurol Taiwan       Date:  2009-03

6.  Headache as presenting symptom of neurosarcoidosis.

Authors:  M Curone; V Tullo; C Peccarisi; G Bussone; D D'Amico
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

7.  Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group.

Authors:  Barney J Stern; Walter Royal; Jeffrey M Gelfand; David B Clifford; Jinny Tavee; Siddharama Pawate; Joseph R Berger; Allen J Aksamit; Allan Krumholz; Carlos A Pardo; David R Moller; Marc A Judson; Marjolein Drent; Robert P Baughman
Journal:  JAMA Neurol       Date:  2018-12-01       Impact factor: 18.302

Review 8.  Management of neurosarcoidosis: a clinical challenge.

Authors:  Mareye Voortman; Marjolein Drent; Robert P Baughman
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.